周一，H.C. Wainwright在Krystal Biotech（NASDAQ:KRYS）欧洲监管进程取得积极进展后，重申了对该公司的"买入"评级和221.00美元的目标价。根据 InvestingPro 数据，这家市值51.6亿美元的生物科技公司展现出令人印象深刻的财务指标。该公司保持着强劲的财务健康状况，整体评分为"优秀"，毛利率高达93%。Krystal ...

市值50亿美元、毛利率高达93%且根据 InvestingPro 评估财务状况"优秀"的生物科技公司Krystal Biotech Inc. (NASDAQ: KRYS )的首席会计官Kathryn ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

2025年2月28日， Krystal Biotech（KRYS）披露18笔公司内部人交易情况。持股10%以上股东Krishnan Suma于2025年2月28日卖出1.21万股。

Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

Thank you for holding. We look forward to talking with you soon. Please hold the line and we'll be right back with you. Thank you for standing by and welcome to the Krystal Biotech Q4 2024 earnings ...